spacer
home > ict > spring 2008 > the fibrotic process
PUBLICATIONS
International Clinical Trials

The Fibrotic Process

Assessing liver fibrosis in clinical trials, William Rosenberg of University College London points to the impact made by individual direct markers

Chronic liver disease is now the second most common cause of death in middle-aged men and the fifth most common cause of death in the UK overall. Out of the top five causes of death it is the only disease that is increasing. The pharmaceutical and biotechnology industries are recognising the worldwide impact of chronic viral hepatitis, alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD) as well as the earning potential for new therapeutic interventions and diagnostic tests. The development of new drugs in particular is dependent on the availability of biomarkers that permit the earliest possible ‘go/no-go’ decisions and provide evidence of efficacy which ensure that drug development is rapid, efficient and safe.

The clinical impact of all chronic liver diseases (CLD) can be attributed to liver fibrosis that may progress to cirrhosis, which in turn results in the complications of portal hypertension (bleeding varices, ascites or encephalopathy), liver failure, hepatocellular cancer and death or liver transplantation. It has been recognised for decades that interventions directed at the causes of CLD can reverse the consequences of liver disease by reversing liver fibrosis. This has been established in clinical trials for the use of anti-viral agents for hepatitis B or hepatitis C, for life modifications including abstinence from alcohol and weight reduction and is integral to the investigation of drugs targeting insulin resistance that underlies NAFLD.

Now, insights into the biology of liver fibrosis have created the possibility of developing anti-fibrotic drugs that target hepatic stellate cells that are central to the production and degradation of liver matrix in fibrosis. The development of this new class of drugs targeted at the fibrotic process rather than individual causes of CLD that have broad applicability, is dependent on accurate biomarkers that are fit for purpose for use in clinical trials.

LIVER BIOPSY

For almost half a century the liver biopsy has been regarded as the standard method for assessing liver fibrosis. Careful histological examination of a biopsy by an expert pathologist remains a vital asset in the diagnosis of liver disease. However, the place of liver biopsy in the assessment of liver fibrosis is increasingly questioned. Recent research has shown that liver biopsy is associated with many problems. For the patient and funder it is painful, hazardous and costly.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor William Rosenberg founded iQur Ltd in 2003, a biotechnology company specialising in diagnostic testing for hepatitis C and other chronic liver diseases. An active academic clinician, he is Deputy Director of the Institute of Hepatology at University College London. He is an experienced Chief Investigator in many multicentre clinical trials and studies investigating diagnostic tests. As Deputy Director of UKCRN, William leads on experimental medicine, a role that aims to ensure that developments in basic science can feed through into clinically relevant research and provide new insights into basic science.
spacer
Professor William Rosenberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement